Tumors of the Female Reproductive Organs

  • Kathi D. Clement
  • Ronald L. Malm
Chapter

Abstract

Common tumors of the female reproductive system include leiomyomas and cervical, endometrial, and ovarian carcinomas.

Keywords

Ovarian Cancer Cervical Cancer Endometrial Cancer Human Papilloma Virus Obstet Gynecol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sener AB, Seckin NC, Ozman S, et al. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Fértil Steril 1996; 65: 354–7.PubMedGoogle Scholar
  2. 2.
    Weinreb JC, Barkoff ND, Megibow A, et al. The value of MR imaging in distinguishing leiomyomas from other solid pelvic masses when sonography is indeterminate. AJR 1990; 154: 295–9.PubMedCrossRefGoogle Scholar
  3. 3.
    American College of Obstetricians and Gynecologists. Surgical alternatives to hysterectomy in the management of leiomyomas ACOG practice bulletin 16. Washington, DC: ACOG, May 2000: 1–10.Google Scholar
  4. 4.
    Candiani GB, Fedele L, Parazzini F, et al. Risk of recurrence after myomectomy. Br J Obstet Gynaecol 1991; 98: 385–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Friedman AJ, Hoffman DI, Comité F, et al. Treatment of leio-myomata uteri with leuprolide acetate depot: a double blind, placebo-controlled, multicenter study: the leuprolide study group. Obstet Gynecol 1991; 77: 720–5.PubMedGoogle Scholar
  6. 6.
    Stovall TG, Ling FW, Henry LC, et al. A randomized trial evaluation: leuprolide acetate before hysterectomy as treatment for leiomyomas. Am J Obstet Gynecol 1991: 164: 1420–3.PubMedCrossRefGoogle Scholar
  7. 7.
    Pace JN, Miller JL, Rose LI. GnRH agonists: gonadorelin, leuprolide, and nafarelin. Am Fam Physician 1991; 44: 1777–82.PubMedGoogle Scholar
  8. 8.
    Physicians’ desk reference, 55th ed. Montvale, NJ: Medical Economics, 2001: 3176.Google Scholar
  9. 9.
    Friedman AF, Lobel SM, Rein MS, et al. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotrophin-releasing hormone agonists: the estrogen threshold hypothesis. Am J Obstet Gynecol 1990; I63: 1114–9.CrossRefGoogle Scholar
  10. 10.
    Barbieri RL. Gonadotrophin-releasing hormone agonists and estrogen-progesterone replacement therapy. Am I Obstet Gynecol 1990; 162: 593–5.CrossRefGoogle Scholar
  11. 11.
    Zullo F, Pellicano M, De Stefano R, et al. A prospective randomized study to evaluate leuprolide acetate treatment before laparoscopic myomectomy: efficacy and ultrasonographic predictors. Am J Obstet Gynecol 1998; 178: 108–12.PubMedCrossRefGoogle Scholar
  12. 12.
    Greenlee R, Hill-Harmon M, Murray T, et al. Cancer statistics 2001. CA Cancer J Clin 2001; 51 (1): 15–36.PubMedCrossRefGoogle Scholar
  13. 13.
    Lungu O. Sun XW, Felix J, et al. Relationship of human papillomavirus type to grade of cervical intraepithelial neoplasia. JAMA 1992; 267: 2493–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Brinton LA, Frammeni JF. Epidemiology of uterine cervical cancer. J Chronic Dis 1986;39:1051–68. “Google Scholar
  15. 15.
    Centers for Disease Control. Black-white differences in cervical cancer mortality: United States, 1980–1987. MMWR 1990; 39: 245–8.Google Scholar
  16. 16.
    Moscicki A, Palefsky JM, Gonzales J, et al. The association between human papillomavirus, deoxyribonucleic acid status, and the results of cytologic rescreening tests in young, sexually active women. Am J Obstet Gynecol 1991; 165: 67–71.PubMedCrossRefGoogle Scholar
  17. 17.
    Carmichael JA, Maskens PD. Cervical dysplasia and human papillomavirus. Am J Obstet Gynecol 1989; 160: 916–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Slattery ML, Robison LM, Schuman KL, et al. Cigarette smoking and exposure to passive smoke are risk factors for cervical cancer. JAMA 1989; 261: 1593–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Brinton LA, Schairer C, Haenszel W, et al. Cigarette smoking and invasive cervical cancer. JAMA 1986; 255: 3265–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Brinton LA, Juggin GR, Lehman HF, et al. Long-term use of oral contraceptives and risk of invasive cervical cancer. Int J Cancer 1986: 38: 339 44.Google Scholar
  21. 21.
    Devesa SS, Young JL, Brinton LA, et al. Recent trends in cervix uteri cancer. CA Cancer J Clin 1989; 64: 2184–90.Google Scholar
  22. 22.
    Boring CC, Squires TS, Tong T. Cancer statistics: 1992. CA Cancer J Clin 1992; 42: 13–38.Google Scholar
  23. 23.
    Nelson JH, Averette HE, Richart RM. Cervical intraepithelial neoplasia (dysplasia and carcinoma in situ) and early invasive cervical carcinoma. CA Cancer J Clin 1989; 39: 157–78.PubMedCrossRefGoogle Scholar
  24. 24.
    Bishop JW, Bigner SH, Colgan JJ. Multicenter masked evaluation of AutoCyte PREP thin layers with matched conventional smears including initial biopsy results. Acta Cytol 1998; 42: 189–97.PubMedCrossRefGoogle Scholar
  25. 25.
    Lee KR, Ashfaq R, Birdsong GG, et al. Comparison of conventional Papanicolaou smears and a fluid-based thin-layer system for cervical cancer screening. Obstet Gynecol 1997; 90: 278–84.PubMedCrossRefGoogle Scholar
  26. Sherman ME, Schiffman MH. Lorincz AT, et al. Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. Cancer 1997;81 (2):89–97.Google Scholar
  27. 27.
    Baldauf JJ, Dreyfus M, Ritter J, et al. Cervicography. Does it improve cervical cancer screening? Acta Cytol 1997; 41: 295–301.PubMedCrossRefGoogle Scholar
  28. 28.
    Kaferle JF, Malouin JM. Evaluation and management of the AGUS Papanicolaou smear. Am Fam Physician 2001;63:223SM4.Google Scholar
  29. 29.
    Kurman RJ, Henson DE. Herbst AL, et al. Interim guideline for management of abnormal cervical cytology. JAMA 1994;271: 1866.Google Scholar
  30. 30.
    Benedet JL, Selke PA, Nickerson KG. Colposcopic evaluation of abnormal Papanicolaou smears in pregnancy. Am J Obstet Gynecol 1987; 157: 932–7.PubMedGoogle Scholar
  31. 31.
    Stafl A, Mattingly RF. Angiogenesis of cervical neoplasia. Am J Obstet Gynecol 1975; 121: 845–51.PubMedGoogle Scholar
  32. 32.
    Wright TC, Gagnon S, Ferenczy AF, et al. Excising CIN lesions by loop electrosurgical procedure. Contemp Obstet Gynecol 1991; 36: 57–73.Google Scholar
  33. 33.
    Wright TC, Gagnon MD, Richart RM, et al. Treatment of cervical intraepithelial neoplasia using the loop electrosurgical excision procedure. Obstet Gynecol 1992; 79: 173–8.PubMedGoogle Scholar
  34. 34.
    Stringer CA. When the Pap is positive: confirming the diagnosis, verifying extent of disease. Prim Care Cancer 1989; 9: 15–18.Google Scholar
  35. 35.
    Cervix uteri. In: American Joint Committee on Cancer: AJCC cancer staging manual, 5th ed. Philadelphia: Lippincott-Raven, 1997; 189–94.Google Scholar
  36. 36.
    Kim SH, Choi BI, Lee HP, et al. Uterine cervical carcinoma: comparison of CT and MR findings. Radiology 1990; 175: 45–51.PubMedGoogle Scholar
  37. 37.
    Perez CA, Zivnuska F, Askin F, Kumar B. Camel HM, Powers WE. Prognostic significance of endometrial extension from primary carcinoma of the uterine cervix. CA Cancer J Clin 1975; 35: 1493–504.Google Scholar
  38. 38.
    Lifshitz S, Buchsbaum HJ. The spread of cervical carcinoma. In: Sciarra J, ed. Gynecology and obstetrics. Philadelphia: Lip-pincott, 1999;7(4):l-3.Google Scholar
  39. 39.
    Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340: 1137–43.PubMedCrossRefGoogle Scholar
  40. 40.
    Van Nagell JR, Parker JC, Maruyama Y, Utley J, Luckett P. Bladder or rectal injury following radiation therapy for cervical cancer. Am J Obstet Gynecol 1974; 119: 727–32.PubMedGoogle Scholar
  41. 41.
    American Cancer Society. Cancer facts and figures 2001. Atlanta, GA: American Cancer Society, 2001.Google Scholar
  42. 42.
    Fu YS, Gambone JC, Berek JS. Pathophysiology and management of endometrial hyperplasia and carcinoma. West J Med 1990; 153: 50–61.PubMedGoogle Scholar
  43. 43.
    Whitehead M, Fraser D. Controversies concerning the safety of estrogen replacement therapy. Am J Obstet Gynecol 1987; 156: 1313–22.PubMedGoogle Scholar
  44. 44.
    Gal D. Endometrial hyperplasia: diagnosis and management. In: Sciarra J, ed. Gynecology and obstetrics. Philadelphia: Lippin-cott, 1999;(4)13:1–11. ’Google Scholar
  45. 45.
    Silverberg SG. Hyperplasia and carcinoma of the endometrium. Semin Diagn Pathol 1988; 5: 135.PubMedGoogle Scholar
  46. 46.
    Gursberg SB, Chen SY, Cohen CJ. Endometrial cancer: factors influencing the choice of treatment. Gynecol Oncol 1974; 2: 308–13.CrossRefGoogle Scholar
  47. 47.
    Ferenczy A. Methods for detecting endometrial carcinoma and its precursors. In: Buchsbaum HJ, Sciarra J, eds. Gynecology and obstetrics. New York: Harper & Row, 1982; 4: 1–8.Google Scholar
  48. 48.
    Gilman CJ. Management of early-stage endometrial carcinoma. Am Fam Physician 1987; 35: 103–12.PubMedGoogle Scholar
  49. 49.
    Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984; 64: 417–20.PubMedGoogle Scholar
  50. 50.
    Damon A. Host factors in cancer of the breast and uterine cervix. J Natl Cancer Inst 1960; 24: 483–516.PubMedGoogle Scholar
  51. 51.
    Wynder EL, Escher GC, Mantel N. An epidemiologic investigation of cancer of the endometrium. Cancer 1966; 19: 489–520.PubMedCrossRefGoogle Scholar
  52. 52.
    Dunn LJ, Bradbury JT. Endocrine factors in endometrial carcinoma: a preliminary report. Am J Obstet Gynecol 1967; 97: 465–71.PubMedGoogle Scholar
  53. 53.
    Hershcopf RJ, Bradlow HL. Obesity, diet, endogenous estrogens, and the risk of hormone-sensitive cancer. Am J Clin Nutr 1987; 45: 283–9.PubMedGoogle Scholar
  54. 54.
    Schapira DV, Jumar NB, Lyman GH, Cavanagh D, Roberts WS, LaPolla J. Upper-body fat distribution and endometrial cancer risk. JAMA 1991; 226: 1808–11.CrossRefGoogle Scholar
  55. 55.
    Lucas WE. The epidemiology of endometrial cancer. In: Sciarra J, ed. Gynecology and obstetrics. Philadelphia: Lippincott, 1990; 7–10.Google Scholar
  56. 56.
    Staszewski J. Breast cancer and body build. Prev Med 1977; 6: 410–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Fisher B, Constantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NS- ABP) B-14. J Natl Cancer Inst 1994; 86: 527.PubMedCrossRefGoogle Scholar
  58. 58.
    Parazini F, La Vecchia C, Negri E, Fedele L, Balotta F. Reproductive factors and risk of endometrial cancer. Am J Obstet Gynecol 1991; 164: 522–7.CrossRefGoogle Scholar
  59. 59.
    Elwood JM, Cole P, Rothman KJ, Kaplan SD. Epidemiology of endometrial cancer. J Natl Cancer Inst 1977; 59: 1055–60.PubMedGoogle Scholar
  60. 60.
    Koonings PP, Grimes DA. Endometrial sampling techniques for the office. Am Fam Physician 1989; 40: 207–10.PubMedGoogle Scholar
  61. 61.
    Lacey CG. Premalignant and malignant disorders of the uterine corpus. In: Pernoll MI, ed. Current obstetrics and gynecologic diagnosis and treatment. Norwalk, CT: Appleton & Lange, 1998; 937–52.Google Scholar
  62. 62.
    American College of Obstetricians and Gynecologists. Carcinoma of the endometrium. Technical bulletin no. 162. Washington, DC: ACOG, 1991.Google Scholar
  63. 63.
    Canavan TP, Doshi NR. Endometrial cancer. Am Fam Physician 1999; 59: 3069–76.PubMedGoogle Scholar
  64. 64.
    Nasri MN. The role of vaginal scan in measurement of endometrial thickness in postmenopausal women. Br J Obstet Gynaecol 1991; 98: 470.PubMedCrossRefGoogle Scholar
  65. 65.
    Ascher SM, Frost AR, Garra BS, Potkul R, Zeman RK. Endometrial ultrasound of the uterus: correlation with histopathol-ogy. J Ultrasound Med 1992; 11: 1159.Google Scholar
  66. 66.
    Volksen M, Dietrich M, Osmers R, Kuhn W. Early diagnosis of carcinomas of the endometrium via transvaginal sonography. J Ultrasound Med 1992; 11: 1155.Google Scholar
  67. 67.
    Varner RE, Sparks JM, Cameron CD, et al. Transvaginal sonography of the endometerium in postmenopausal women. Obstet Gynecol 1991; 78: 195.PubMedGoogle Scholar
  68. 68.
    Loffer FD. Hysteroscopy with selective endometrial sampling compared with D and C for abnormal uterine bleeding: the value of a negative hysteroscopic view. Obstet Gynecol 1989: 73: 16.PubMedGoogle Scholar
  69. 69.
    Boronow RC. Advances in diagnosis, staging, and management of cervical and endometrial cancer, stages 1 and II. Cancer 1990; 65 (suppl 3): 648–59.PubMedCrossRefGoogle Scholar
  70. 70.
    Berchuck A. Post-treatment surveillance of patients with early-stage endometrial cancer. Gynecol Oncol 1995; 59: 20–4.PubMedCrossRefGoogle Scholar
  71. 71.
    Oram DH, Jacobs IJ, Brady JL, Prys-Davies A. Early diagnosis of ovarian cancer. Br J Hosp Med 1990; 44: 320–4.PubMedGoogle Scholar
  72. 72.
    Piver MS, Baker TR, Piedmonte M, Sandecki AM. Epidemiology and etiology of ovarian cancer. Semin Oncol 1991; 18: 177–85.PubMedGoogle Scholar
  73. 73.
    Pike MC. Age-related factors in cancers of the breast, ovary, and endometrium. J Chronic Dis 1987; 40 (suppl 2): 59S - 69S.PubMedCrossRefGoogle Scholar
  74. 74.
    Partridge EE, Barnes MN. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J Clin 1999; 49: 297–320.PubMedCrossRefGoogle Scholar
  75. 75.
    Modan B, I-Iartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:235).Google Scholar
  76. 76.
    Bourne T, Reynolds K, Campbell S. Ovarian cancer. Eur J Cancer 1991; 27: 655–9.PubMedCrossRefGoogle Scholar
  77. 77.
    Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials. N Engl J Med 1990; 322: 1021–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Bast RC, Jacobs I. The CA-125 tumor associated antigen: a review of the literature. Hum Reprod 1989; 4: 1.PubMedCrossRefGoogle Scholar
  79. 79.
    Friedlander ML, Dembo AJ. Prognostic factors in ovarian cancer. Semin Oncol 1991; 18: 205–12.PubMedGoogle Scholar
  80. 80.
    Campbell S, Goessens L, Goswamy R, Whitehead MI. Realtime ultrasonography for determination of ovarian morphology and volume: a possible new screening test for ovarian cancer? Lancet 1982; 1: 425–6.PubMedCrossRefGoogle Scholar
  81. 81.
    Averette HE, Donato DM. Ovarian carcinoma. Cancer 1990; 65 (suppl 3): 703–8.PubMedCrossRefGoogle Scholar
  82. 82.
    Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the gynecologic oncology group experience. J Clin Oncol 1991; 9: 1138–50.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Kathi D. Clement
  • Ronald L. Malm

There are no affiliations available

Personalised recommendations